Immuneering (IMRX) Competitors

$5.15 -0.23 (-4.20%)

As of 03:29 PM Eastern

IMRX vs. WVE, GHRS, MLTX, MAZE, and MPLT

Should you buy Immuneering stock or one of its competitors? MarketBeat compares Immuneering with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immuneering include WAVE Life Sciences (WVE), GH Research (GHRS), MoonLake Immunotherapeutics (MLTX), Maze Therapeutics (MAZE), and Maplight Therapeutics (MPLT). These companies are all part of the "pharmaceutical products" industry.

How does Immuneering compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, WAVE Life Sciences had 1 more articles in the media than Immuneering. MarketBeat recorded 3 mentions for WAVE Life Sciences and 2 mentions for Immuneering. Immuneering's average media sentiment score of 0.94 beat WAVE Life Sciences' score of 0.69 indicating that Immuneering is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Immuneering's return on equity of -43.33% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Immuneering	N/A	-43.33%	-39.75%

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 22.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immuneering has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$71.80M	18.58	-$204.38M	-$1.06	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.38	N/A

WAVE Life Sciences has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

WAVE Life Sciences presently has a consensus target price of $27.50, indicating a potential upside of 296.54%. Immuneering has a consensus target price of $16.50, indicating a potential upside of 220.14%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

WAVE Life Sciences and Immuneering tied by winning 8 of the 16 factors compared between the two stocks.

How does Immuneering compare to GH Research?

GH Research (NASDAQ:GHRS) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

GH Research is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.80	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.38	N/A

GH Research's return on equity of -16.30% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-16.30%	-15.77%
Immuneering	N/A	-43.33%	-39.75%

GH Research presently has a consensus target price of $40.13, indicating a potential upside of 82.51%. Immuneering has a consensus target price of $16.50, indicating a potential upside of 220.14%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

56.9% of GH Research shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 22.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GH Research has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

In the previous week, GH Research had 1 more articles in the media than Immuneering. MarketBeat recorded 3 mentions for GH Research and 2 mentions for Immuneering. GH Research's average media sentiment score of 1.89 beat Immuneering's score of 0.94 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GH Research beats Immuneering on 9 of the 14 factors compared between the two stocks.

How does Immuneering compare to MoonLake Immunotherapeutics?

Immuneering (NASDAQ:IMRX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

In the previous week, MoonLake Immunotherapeutics had 25 more articles in the media than Immuneering. MarketBeat recorded 27 mentions for MoonLake Immunotherapeutics and 2 mentions for Immuneering. Immuneering's average media sentiment score of 0.94 beat MoonLake Immunotherapeutics' score of 0.59 indicating that Immuneering is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	7 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

67.7% of Immuneering shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 22.9% of Immuneering shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.38	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Immuneering's return on equity of -43.33% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-43.33%	-39.75%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Immuneering has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

Immuneering currently has a consensus target price of $16.50, indicating a potential upside of 220.14%. MoonLake Immunotherapeutics has a consensus target price of $23.85, indicating a potential upside of 29.03%. Given Immuneering's stronger consensus rating and higher probable upside, equities research analysts plainly believe Immuneering is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Immuneering beats MoonLake Immunotherapeutics on 10 of the 14 factors compared between the two stocks.

How does Immuneering compare to Maze Therapeutics?

Immuneering (NASDAQ:IMRX) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

In the previous week, Maze Therapeutics had 3 more articles in the media than Immuneering. MarketBeat recorded 5 mentions for Maze Therapeutics and 2 mentions for Immuneering. Immuneering's average media sentiment score of 0.94 beat Maze Therapeutics' score of 0.13 indicating that Immuneering is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.7% of Immuneering shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immuneering has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.38	N/A
Maze Therapeutics	$167.50M	7.82	-$131.12M	-$3.23	N/A

Maze Therapeutics' return on equity of -36.89% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-43.33%	-39.75%
Maze Therapeutics	N/A	-36.89%	-32.74%

Immuneering has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market.

Immuneering currently has a consensus target price of $16.50, indicating a potential upside of 220.14%. Maze Therapeutics has a consensus target price of $66.00, indicating a potential upside of 150.59%. Given Immuneering's higher possible upside, analysts plainly believe Immuneering is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Maze Therapeutics beats Immuneering on 8 of the 15 factors compared between the two stocks.

How does Immuneering compare to Maplight Therapeutics?

Immuneering (NASDAQ:IMRX) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

In the previous week, Maplight Therapeutics had 16 more articles in the media than Immuneering. MarketBeat recorded 18 mentions for Maplight Therapeutics and 2 mentions for Immuneering. Immuneering's average media sentiment score of 0.94 beat Maplight Therapeutics' score of 0.13 indicating that Immuneering is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	1 Very Positive mention(s)	9 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuneering currently has a consensus target price of $16.50, indicating a potential upside of 220.14%. Maplight Therapeutics has a consensus target price of $34.43, indicating a potential upside of 18.43%. Given Immuneering's stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Immuneering is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.38	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A

67.7% of Immuneering shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Maplight Therapeutics' return on equity of 0.00% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-43.33%	-39.75%
Maplight Therapeutics	N/A	N/A	N/A

Summary

Immuneering beats Maplight Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Immuneering News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRX vs. The Competition

Export

Metric	Immuneering	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$334.18M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-3.74	18.77	20.85	25.56
Price / Sales	N/A	263.59	543.57	72.25
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.52	6.77	9.87	6.72
Net Income	-$56.03M	$24.11M	$3.55B	$333.62M
7 Day Performance	-1.26%	0.17%	-0.23%	0.35%
1 Month Performance	-4.73%	0.98%	1.47%	4.00%
1 Year Performance	309.05%	78.11%	41.05%	36.32%

Immuneering Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRX Immuneering	2.2719 of 5 stars	$5.15 -4.2%	$16.50 +220.1%	+320.3%	$334.18M	N/A	N/A	60
WVE WAVE Life Sciences	2.7611 of 5 stars	$6.83 -3.5%	$27.50 +302.9%	+9.4%	$1.32B	$42.73M	N/A	240
GHRS GH Research	3.8157 of 5 stars	$21.17 -0.4%	$40.13 +89.5%	+117.5%	$1.31B	N/A	N/A	10	Earnings Report
MLTX MoonLake Immunotherapeutics	3.4226 of 5 stars	$18.18 -3.5%	$23.85 +31.2%	-52.2%	$1.31B	N/A	N/A	2	Trending News Earnings Report Analyst Forecast Analyst Revision
MAZE Maze Therapeutics	2.3651 of 5 stars	$25.70 +0.7%	$66.00 +156.9%	+173.4%	$1.28B	N/A	N/A	121	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuneering (IMRX) Competitors

IMRX vs. WVE, GHRS, MLTX, MAZE, and MPLT

How does Immuneering compare to WAVE Life Sciences?

Summary

How does Immuneering compare to GH Research?

Summary

How does Immuneering compare to MoonLake Immunotherapeutics?

Summary

How does Immuneering compare to Maze Therapeutics?

Summary

How does Immuneering compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuneering (IMRX) Competitors

IMRX vs. WVE, GHRS, MLTX, MAZE, and MPLT

How does Immuneering compare to WAVE Life Sciences?

Does the media prefer WVE or IMRX?

Is WVE or IMRX more profitable?

Do institutionals and insiders believe in WVE or IMRX?

Which has better valuation and earnings, WVE or IMRX?

Which has more volatility & risk, WVE or IMRX?

Do analysts recommend WVE or IMRX?

Summary

How does Immuneering compare to GH Research?

Which has better valuation and earnings, GHRS or IMRX?

Is GHRS or IMRX more profitable?

Do analysts recommend GHRS or IMRX?

Do institutionals and insiders believe in GHRS or IMRX?

Which has more volatility & risk, GHRS or IMRX?

Does the media prefer GHRS or IMRX?

Summary

How does Immuneering compare to MoonLake Immunotherapeutics?

Does the media favor IMRX or MLTX?

Do insiders & institutionals believe in IMRX or MLTX?

Which has stronger earnings & valuation, IMRX or MLTX?

Is IMRX or MLTX more profitable?

Which has more risk and volatility, IMRX or MLTX?

Do analysts rate IMRX or MLTX?

Summary

How does Immuneering compare to Maze Therapeutics?

Does the media refer more to IMRX or MAZE?

Do institutionals & insiders believe in IMRX or MAZE?

Which has higher earnings and valuation, IMRX or MAZE?

Is IMRX or MAZE more profitable?

Which has more risk & volatility, IMRX or MAZE?

Do analysts rate IMRX or MAZE?

Summary

How does Immuneering compare to Maplight Therapeutics?

Does the media refer more to IMRX or MPLT?

Do analysts rate IMRX or MPLT?

Which has higher earnings and valuation, IMRX or MPLT?

Do institutionals & insiders believe in IMRX or MPLT?

Is IMRX or MPLT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools